	US 11,730,744 B2
	Methods of reducing risk of preterm birth
Robert Birch, Saint Charles, MO (US); and Michael J. Jozwiakowski, Sudbury, MA (US)
Assigned to COVIS PHARMA GMBH, Zug (CH)
Filed by COVIS Pharma GmbH, Zug (CH)
Filed on Apr. 30, 2021, as Appl. No. 17/245,904.
Application 17/245,904 is a continuation of application No. 16/580,669, filed on Sep. 24, 2019, granted, now 11,154,562.
Application 16/580,669 is a continuation of application No. 15/709,941, filed on Sep. 20, 2017, granted, now 10,471,075, issued on Nov. 12, 2019.
Application 15/709,941 is a continuation of application No. 15/143,867, filed on May 2, 2016, abandoned.
Claims priority of provisional application 62/250,189, filed on Nov. 3, 2015.
Claims priority of provisional application 62/155,076, filed on Apr. 30, 2015.
Prior Publication US 2021/0353644 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 47/44 (2017.01); A61K 47/14 (2017.01); A61K 31/57 (2006.01)

CPC A61K 31/573 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/57 (2013.01); A61K 47/14 (2013.01); A61K 47/44 (2013.01)]

16 Claims

1. A method of reducing the risk of preterm birth in a pregnant human patient, comprising: subcutaneously administering to a pregnant human patient a 1.1 mL dose comprising a pharmaceutically acceptable non-aqueous formulation comprising 275 mg 17-α hydroxyprogesterone caproate,

wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient an AUC_1-tof between about 120% to about 88% compared to an AUC_0-tof the patient administered the same dosage amount of hydroxyprogesterone caproate intramuscularly.